You started testosterone therapy expecting sharper recovery and a steadier drive. Instead, after adding an aromatase inhibitor, your joints ache, your mood flattens, and libido drops. That is not the protocol working harder. That is estradiol pushed too low, and it deserves the same respect as any other lab out of range.
The optimizer's blind spot: estrogen is not the enemy
In men, a portion of testosterone is converted into estradiol by an enzyme called aromatase, which is expressed heavily in fat tissue, bone, and the brain [1]. This is not a side effect to be eliminated. Estradiol is a working hormone in the male body. It contributes to bone density, joint comfort, cognition, and sexual function [1][2].
The internet version of hormone optimization often frames estrogen as something to crush. A high-performer who reads forums may reach for an aromatase inhibitor (AI) at the first sign of any estradiol rise, treating a lower number as a cleaner protocol. The physiology says otherwise. Both ends of the estradiol range carry consequences, and driving it toward the floor creates its own set of problems.
A landmark study in the New England Journal of Medicine used a design that separated the effects of testosterone from the effects of its conversion to estradiol. When estradiol production was blocked, men experienced changes in body composition and, notably, a decline in sexual desire and function that tracked with the loss of estrogen, not testosterone [3]. In other words, some of what men attribute to testosterone is actually estradiol doing its job.
Source: [3] Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men (NEJM)
What an estrogen crash actually feels like
When estradiol is suppressed too aggressively, the pattern is fairly consistent and, frustratingly, overlaps with the symptoms of low testosterone itself:
- Joint pain and stiffness. Estrogen supports connective tissue and joint comfort. Aromatase inhibitors are well documented to cause arthralgia (joint pain), a finding established in the oncology literature where AIs are used at scale [4].
- Low libido and erectile changes. The mechanism traced in controlled research links falling estradiol directly to reduced sexual desire [3].
- Mood disruption. Estradiol interacts with mood-regulating pathways in the brain, and men report low mood and irritability when it is driven down [2].
- Bone concerns over time. Estrogen is the dominant regulator of bone maintenance in men, not testosterone. Very low estradiol is associated with reduced bone mineral density [1][2].
The cruel irony for a dialed-in optimizer is this: the fix that was supposed to sharpen you can produce a symptom picture that looks exactly like the problem you started with. That is why an over-suppressed estradiol is treated as its own clinical problem, not a milestone.
Why a provider treats "low estrogen" as a red flag, not a win
An independent, physician-led provider does not chase a single number to zero. The goal is balance across the full hormone picture, which is exactly the depth a serious optimizer is looking for. A few principles that shape how estradiol is approached in a supervised setting:
Symptoms are read alongside labs, not instead of them. A number on a page means little without the person attached to it. Joint pain, mood, and libido are data points a provider weighs against measured estradiol.
Aromatase inhibitors are a decision, not a default. Guidance from the Endocrine Society on testosterone therapy in men emphasizes monitoring and individualized management rather than reflexive estrogen suppression [5]. An AI is a potent medication with real downside when misapplied.
Assay quality matters. Standard estradiol tests were designed for the higher levels seen in women and can be unreliable at the lower concentrations typical in men. This is a known limitation, and it is one reason a casual online lab result can mislead someone into "correcting" a number that was never accurate to begin with [1].
The fertility question every athlete should ask first
For a younger athlete who has watched a peer's gray-market cycle end in infertility, this is the part that matters most. Exogenous testosterone signals the brain to shut down its own production line. That suppression lowers the pituitary hormones (LH and FSH) that drive the testes, and it can sharply reduce sperm production. The American Urological Association is direct about this: testosterone therapy should not be prescribed to men who are currently trying to conceive, precisely because of its effect on fertility [6].
That does not mean every hormone conversation is a dead end for fertility, but it does mean the strategy has to be built with fertility in mind from day one, under supervision, with the right baseline testing. This is the entire difference between the gym shortcut and a legitimate path: someone is looking at the whole system, including the parts you cannot feel until it is too late.
Source: [6] Evaluation and Management of Testosterone Deficiency: AUA Guideline
What responsive monitoring looks like
Optimization is not a one-time prescription. It is a loop: test, interpret, adjust, retest. In a supervised setting that loop typically includes:
- A baseline panel before anything starts, including total and free testosterone, estradiol, and a hematocrit/hemoglobin check, plus fertility markers where relevant [5][6].
- Follow-up labs after changes, because hematocrit can rise on testosterone therapy and needs to be watched to reduce cardiovascular risk [5].
- Estradiol read in context, not chased to a target floor.
- Symptom tracking between visits so the protocol responds to how you actually feel, not just an annual snapshot.
The responsiveness is the point. A protocol that is set once and revisited a year later cannot manage a hormone as dynamic as estradiol.
Source: [5] Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline, [6] Evaluation and Management of Testosterone Deficiency: AUA Guideline
The bottom line
If you added an aromatase inhibitor and feel worse (achy joints, flat mood, absent libido), the most likely explanation is not that your protocol needs to push harder. It is that estradiol has a job, and it has been pushed below where it can do that job. A thoughtful provider reads that as a problem to correct, with the same seriousness as any other out-of-range value.
This article is educational and is not medical advice. Decisions about testosterone, aromatase inhibitors, and estradiol management should be made with an independent licensed provider who knows your labs and history.
Where Velri fits
Velri is a technology and coordination company, not a medical provider. Velri does not practice medicine or dispense medication. What Velri coordinates is the infrastructure a serious optimizer wants: baseline and follow-up lab work, a visit with an independent, physician-led Provider Group, and, if a provider decides it is appropriate, fulfillment through an independent, licensed pharmacy. Whether any medication is prescribed is always the decision of an independent licensed provider, and a prescription is never guaranteed.
Where compounded medications are involved: compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state. Coverage currently starts in Nevada, with more states rolling out over time.
